Literature DB >> 20608741

Potent antagonist for the vitamin D receptor: vitamin D analogues with simple side chain structure.

Yuta Sakamaki1, Yuka Inaba, Nobuko Yoshimoto, Keiko Yamamoto.   

Abstract

We previously reported that 22S-butyl-25,26,27-trinor-1alpha,24-dihydroxyvitamin D(3) 2 was a potent VDR antagonist. The X-ray crystal structure of the ligand binding domain of VDR complexed with 2 indicated that this ligand induces an extra cavity within the ligand-binding pocket. The structure also showed that the ligand forms only poor hydrophobic interactions with helix 12 of the protein. Here, to study the effects of the induction of the extra cavity and of insufficient interactions with helix 12 on antagonism, we designed and synthesized a series of vitamin D(3) analogues with or without a 22-alkyl substituent and evaluated their biological potency. We found that the 22-butyl analogues 3c and 5c act as full antagonists, the 22-ethyl analogues 3b, 4b, 5b, and 22-butyl analogue 4c act as partial agonists, and the others (3a, 4a, 5a, 6a, 6b, and 6c) act as full agonists for VDR. It is intriguing that 6c is a potent agonist for VDR, whereas its 26,27-dinor analogue 5c is a potent antagonist. Analogue 6c recruited coactivator SRC-1 well, but 5c did not. These results indicate that a combination of induction of the extra cavity and insufficient hydrophobic interactions with helix 12 is important for VDR antagonism in this class of ligands.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20608741     DOI: 10.1021/jm100649d

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Structure of the full human RXR/VDR nuclear receptor heterodimer complex with its DR3 target DNA.

Authors:  Igor Orlov; Natacha Rochel; Dino Moras; Bruno P Klaholz
Journal:  EMBO J       Date:  2011-12-16       Impact factor: 11.598

2.  Protein kinase Cα and Src kinase support human prostate-distributed dihydrotestosterone-metabolizing UDP-glucuronosyltransferase 2B15 activity.

Authors:  Sunit K Chakraborty; Nikhil K Basu; Sirsendu Jana; Mousumi Basu; Amit Raychoudhuri; Ida S Owens
Journal:  J Biol Chem       Date:  2012-04-24       Impact factor: 5.157

3.  Efficient synthesis of the very-long-chain n-3 fatty acids, tetracosahexaenoic acid (C24:6n-3) and tricosahexaenoic acid (C23:6n-3).

Authors:  Toshimasa Itoh; Ayako Tomiyasu; Keiko Yamamoto
Journal:  Lipids       Date:  2011-02-24       Impact factor: 1.880

4.  A 20S combined with a 22R configuration markedly increases both in vivo and in vitro biological activity of 1α,25-dihydroxy-22-methyl-2-methylene-19-norvitamin D3.

Authors:  Agnieszka Flores; Rafal R Sicinski; Pawel Grzywacz; James B Thoden; Lori A Plum; Margaret Clagett-Dame; Hector F DeLuca
Journal:  J Med Chem       Date:  2012-04-22       Impact factor: 7.446

Review 5.  Strategies for developing pregnane X receptor antagonists: Implications from metabolism to cancer.

Authors:  Sergio C Chai; William C Wright; Taosheng Chen
Journal:  Med Res Rev       Date:  2019-11-28       Impact factor: 12.944

Review 6.  Inhibitors for the Vitamin D Receptor-Coregulator Interaction.

Authors:  Kelly A Teske; Olivia Yu; Leggy A Arnold
Journal:  Vitam Horm       Date:  2015-11-30       Impact factor: 3.421

7.  Vitamin D Receptor Expression in Plasmablastic Lymphoma and Myeloma Cells Confers Susceptibility to Vitamin D.

Authors:  Duncan M Gascoyne; Linden Lyne; Hayley Spearman; Francesca M Buffa; Elizabeth J Soilleux; Alison H Banham
Journal:  Endocrinology       Date:  2017-03-01       Impact factor: 4.736

Review 8.  Vitamin D and Its Synthetic Analogs.

Authors:  Miguel A Maestro; Ferdinand Molnár; Carsten Carlberg
Journal:  J Med Chem       Date:  2019-04-02       Impact factor: 7.446

9.  SPA70 is a potent antagonist of human pregnane X receptor.

Authors:  Wenwei Lin; Yue-Ming Wang; Sergio C Chai; Lili Lv; Jie Zheng; Jing Wu; Qijun Zhang; Yong-Dong Wang; Patrick R Griffin; Taosheng Chen
Journal:  Nat Commun       Date:  2017-09-29       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.